Behind the Money

In this insightful discussion, Stephen Witt, an author and journalist who wrote The Thinking Machine about NVIDIA, dives into the extraordinary rise of the company under Jensen Huang's leadership. He reveals Huang's relentless drive, characterized by a culture of urgency and constant demands for more. Witt explains how NVIDIA transformed gaming chips into a scientific powerhouse and created the AI hardware market from scratch. He also addresses the current competitive landscape and ethical concerns around AI, offering a compelling look at the mind of a visionary leader.

In this insightful discussion, Daniel Sheard, a former asset manager, reveals the high stakes of blowing the whistle on risky investments linked to Greensill, detailing the fallout from regulatory negligence. George Patelis, ex-CEO of Tayuda, shares his harrowing experience of personal and professional ruin after exposing financial irregularities. Martin Arnold, financial regulation expert, contextualizes their struggles within the UK’s inadequate whistleblower system, highlighting the contrast with the more supportive US framework and calling for significant reforms.

In the UK, corporate whistleblowers face a harsh reality—reporting wrongdoing can cost them their jobs and peace of mind. A guest sheds light on the unresolved risks investors face amidst corporate misconduct. The conversation highlights the wider implications of such actions, affecting not only the whistleblower but also their families. This poignant discussion raises important questions about the need for systemic change to support those who step forward.

Discover how Southwest Airlines created a unique business model that shook up the airline industry. Hear about the daring legal battles Herb Kelleher faced to get started and the innovative $10 fares that drew in customers. Explore the playful brand personality that made Southwest memorable, along with a risky operational collapse after a winter storm. As the airline adapts to modern pressures, including assigned seating and evolving strategies, the story highlights the balance between profitability and growth.

David Keohane, FT Tokyo correspondent, and Leo Lewis, Tokyo bureau chief, explore the evolving landscape of private equity in Japan. They discuss the shift from initial skepticism and media criticism to mainstream acceptance of PE, highlighting key demographic changes and labor shortages that make PE's role crucial. The duo delves into Japan’s unique corporate culture, softer takeover methods, and the government's newfound support for PE, while also addressing concerns about potential risks and the future of investment in the region.

Investors are diving into groundbreaking treatments aimed at extending human life. The discussion touches on the shift of anti-aging innovations from the wealthy to the general public. Entrepreneurs envision futuristic rejuvenation pills that promise overnight cellular renewal. Delving into the obsession with longevity, the hosts explore the interplay of wealth, power, and ethical dilemmas. Skepticism arises as they dissect the shady corners of the longevity industry, questioning the trustworthiness of tech companies and their claims.

In this engaging discussion, George Hammond, a venture capital correspondent at the Financial Times, and Tabby Kinder, the U.S. West Coast financial editor, tackle the monumental changes at OpenAI. They delve into the implications of its shift to a for-profit model and the staggering $1.4 trillion in chip and data center deals. The duo also explores potential funding challenges, vendor financing concerns, and whether OpenAI could represent a systemic risk in the tech market. They highlight the race for computational resources among AI startups and what this means for the industry’s future.

In this engaging discussion, Oliver Barnes, U.S. deals and activism correspondent for the Financial Times, delves into the fierce $10 billion battle between Pfizer and Novo Nordisk over the biotech startup MetSera. He outlines why weight-loss drugs have become crucial for both companies and explains the unique bidding strategies employed. Topics include Novo's unsolicited bid, Pfizer's accusations of bribery, and the political drama surrounding the FTC's involvement. With high stakes in play, the showdown reveals the urgent demand for innovative obesity treatments.

Jamie Smyth, the U.S. energy editor at the Financial Times, delves into the intriguing world of Oklo, a nuclear start-up valued at $17 billion yet with no revenue. He discusses its meteoric rise, fueled by AI demands and links to the Trump administration. Smyth uncovers Oklo's unconventional business model, where they plan to sell power directly, bypassing utilities. He also addresses the regulatory challenges and investor concerns regarding safety and timelines, revealing the fragility of Oklo's valuation amidst rising skepticism.

In this insightful discussion, Robert Smith and Ortenca Aliaj, both Financial Times editors, unravel the shocking collapse of First Brands Group, a small auto parts supplier with a staggering $12 billion in hidden debt. They explore the opaque financing tactics that obscured financial risks and discuss the lack of due diligence by lenders. From Patrick James's mysterious background to the broader implications for private credit, they raise critical concerns about the future of funding practices in a post-2008 financial landscape.